{"id":"slo-niacin-atorvastatin","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Flushing"},{"rate":"10-20","effect":"Pruritus"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Myalgia"},{"rate":"3-5","effect":"Elevated liver enzymes"},{"rate":"2-5","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Niacin is a B vitamin that decreases hepatic VLDL production and increases HDL cholesterol through nicotinic acid receptor signaling. Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Together, this combination addresses multiple lipid abnormalities to reduce atherosclerotic cardiovascular disease risk.","oneSentence":"Slo-Niacin (niacin) reduces triglycerides and raises HDL cholesterol, while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and overall cardiovascular risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:24.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia and hypercholesterolemia"},{"name":"Cardiovascular disease prevention"}]},"trialDetails":[{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT00715273","phase":"PHASE4","title":"Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication","status":"COMPLETED","sponsor":"University of Washington","startDate":"2001-05-01","conditions":"Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis","enrollment":217},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT00728910","phase":"PHASE2","title":"Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-06","conditions":"Dyslipidemia","enrollment":25},{"nctId":"NCT00804843","phase":"PHASE2","title":"Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Carotid Atherosclerosis","enrollment":100},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00465088","phase":"PHASE3","title":"An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-04","conditions":"Hyperlipidemia, Mixed Dyslipidemia","enrollment":199},{"nctId":"NCT00150722","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Modulation and Endothelial Function","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2005-09","conditions":"Atherosclerosis","enrollment":75},{"nctId":"NCT00194402","phase":"PHASE4","title":"SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-08","conditions":"Dyslipidemia","enrollment":64},{"nctId":"NCT00458055","phase":"NA","title":"High-Density Lipoprotein (HDL) Treatment Study","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2006-11","conditions":"Coronary Arteriosclerosis, Hypoalphalipoproteinemias, Genetic Diseases, Inborn","enrollment":19},{"nctId":"NCT00079638","phase":"PHASE4","title":"Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"2004-04","conditions":"Dyslipidemia, Coronary Heart Disease, Atherosclerosis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lipitor (R) (Atorvastatin)","Slo-Niacin (R) (time-release niacin"],"phase":"marketed","status":"active","brandName":"Slo-Niacin, atorvastatin","genericName":"Slo-Niacin, atorvastatin","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Slo-Niacin (niacin) reduces triglycerides and raises HDL cholesterol, while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and overall cardiovascular risk. Used for Dyslipidemia and hypercholesterolemia, Cardiovascular disease prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}